Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Herbst

Showing results (21-30 of 395) with videos related to

Pageof 40
Sort By:
Seminars in Oncology|November 8, 2002
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancerRoy S Herbst, Waun Ki Hong
Seminars in Oncology Nursing|June 11, 2002
The role of the epidermal growth factor receptor in the treatment of colorectal carcinomaElizabeth S Waxman, Roy S Herbst
Cancer Treatment Reviews|September 16, 2003
Mode of action of docetaxel - a basis for combination with novel anticancer agentsRoy S Herbst, Fadlo R Khuri
American Journal of Medical Genetics|October 1, 1982
Sib risks for nonspecific mental retardation in British ColumbiaD S Herbst, P A Baird
The Oncologist|August 31, 2002
ZD1839 (Iressa) in non-small cell lung cancerRoy S Herbst, Merrill S Kies
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancerRoy S Herbst, Stanley R Frankel
The Journal of Infusional Chemotherapy|October 1, 1996
Application of ambulatory infusion devices in infusional cancer chemotherapy: a model for nursing managementC Moore, S Herbst, M Lawson
American Journal of Medical Genetics|January 1, 1980
Nonspecific X-linked mental retardation II: the frequency in British ColumbiaD S Herbst, J R Miller
Clinical Lung Cancer|January 21, 2004
Vinorelbine and gemcitabine combinations in advanced non small-cell lung cancerR C Lilenbaum, R S Herbst
Cancer|March 29, 2002
Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapyRoy S Herbst, Dong M Shin
Pageof 40

Showing results (21-30 of 395) with videos related to

Sort By:
Pageof 40
Seminars in Oncology|November 8, 2002
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancerRoy S Herbst, Waun Ki Hong
Seminars in Oncology Nursing|June 11, 2002
The role of the epidermal growth factor receptor in the treatment of colorectal carcinomaElizabeth S Waxman, Roy S Herbst
Cancer Treatment Reviews|September 16, 2003
Mode of action of docetaxel - a basis for combination with novel anticancer agentsRoy S Herbst, Fadlo R Khuri
American Journal of Medical Genetics|October 1, 1982
Sib risks for nonspecific mental retardation in British ColumbiaD S Herbst, P A Baird
The Oncologist|August 31, 2002
ZD1839 (Iressa) in non-small cell lung cancerRoy S Herbst, Merrill S Kies
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancerRoy S Herbst, Stanley R Frankel
The Journal of Infusional Chemotherapy|October 1, 1996
Application of ambulatory infusion devices in infusional cancer chemotherapy: a model for nursing managementC Moore, S Herbst, M Lawson
American Journal of Medical Genetics|January 1, 1980
Nonspecific X-linked mental retardation II: the frequency in British ColumbiaD S Herbst, J R Miller
Clinical Lung Cancer|January 21, 2004
Vinorelbine and gemcitabine combinations in advanced non small-cell lung cancerR C Lilenbaum, R S Herbst
Cancer|March 29, 2002
Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapyRoy S Herbst, Dong M Shin
Pageof 40